ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP)

Historical Holders from Q1 2014 to Q3 2025

Symbol: ORMP on Nasdaq
Type / Class: Equity / Common Stock par value $0.012 per share
Shares outstanding: 41,009,592
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 7,236,876
Holdings value: $19,100,309
% of all portfolios: 0.001%
Number of holders: 46
Number of buys: 13
Number of sells: -15
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
KIDRON NADAV	7.6%		$6,638,633		3,116,729		Nadav Kidron	11 Feb 2025
BML Investment Partners, L.P.	6.55%		$5,816,595		2,643,907		BML Investment Partners, L.P.	31 Dec 2024

Institutional Holders of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	7,236,876	$19,100,309	+$25,894		$0	$2.64	46
2025 Q2	7,251,222	$16,313,647	-$1,132,788	$0	$103,950	$2.25	47
2025 Q1	7,771,787	$16,633,500	+$194,000	$428	$23,968	$2.14	52
2024 Q4	7,666,141	$18,551,607	+$1,150,587	$47,190	$42,108	$2.42	56
2024 Q3	6,959,875	$16,982,253	+$2,490,137	$5,124	$9,760	$2.44	55
2024 Q2	5,933,749	$15,249,519	+$1,726,907	$0	$0	$2.57	58
2024 Q1	5,261,652	$15,365,000	+$367,171	$7,884	$24,236	$2.92	51
2023 Q4	5,157,802	$11,912,739	+$6,481,828	$7,623	$67,683	$2.31	56
2023 Q3	2,294,903	$5,988,449	-$130,636	$17,748	$37,584	$2.61	55
2023 Q2	2,276,672	$8,150,136	-$6,048,074	$15,394	$119,930	$3.58	50
2023 Q1	4,261,808	$9,288,923	-$8,600,260	$45,126	$69,106	$2.18	58
2022 Q4	3,602,106	$43,330,122	+$3,052,928	$2,950,959	$2,289,309	$12.03	75
2022 Q3	3,938,125	$25,517,588	-$15,544,475	$458,000	$694,000	$6.48	66
2022 Q2	6,646,450	$30,636,409	-$17,757,938	$135,000	$572,000	$4.58	81
2022 Q1	9,033,365	$78,273,671	-$349,248	$773,000	$1,760,000	$8.65	99
2021 Q4	8,576,111	$122,411,193	+$40,878,901	$2,285,000	$4,689,796	$14.28	114
2021 Q3	5,412,384	$118,854,258	+$35,544,918	$3,500,000	$8,146,000	$21.98	91
2021 Q2	3,842,761	$51,413,524	+$35,140,443	$839,000	$2,413,000	$13.38	73
2021 Q1	1,235,726	$64,175,840	+$52,410,474	$600,000	$1,959,000	$10.16	43
2020 Q4	1,455,367	$6,169,000	-$1,608,413	$65,000	$299,000	$4.24	36
2020 Q3	2,003,232	$5,190,000	+$1,670,327		$61,000	$2.61	34
2020 Q2	1,349,404	$4,725,000	+$2,515,869		$345,000	$3.53	31
2020 Q1	624,185	$1,899,000	-$91,414	$0	$378,000	$3.04	29
2019 Q4	624,437	$3,215,000	-$401,395	$91,000	$561,000	$5.14	30
2019 Q3	759,036	$2,420,000	-$260,031			$3.19	28
2019 Q2	839,001	$3,010,000	-$842,076			$3.59	26
2019 Q1	1,073,145	$3,905,000	-$2,620,760			$3.64	25
2018 Q4	1,898,942	$5,699,000	+$412,711			$3	24
2018 Q3	1,741,007	$8,449,000	+$7,167,466			$4.85	28
2018 Q2	263,431	$1,958,000	+$6,399			$7.43	21
2018 Q1	256,435	$1,666,000	-$820,544			$6.51	20
2017 Q4	377,714	$3,402,549	+$790,106			$9	27
2017 Q3	274,779	$2,725,000	+$1,262,094			$9.92	22
2017 Q2	148,752	$1,157,000	+$276,760	$3,000		$7.78	21
2017 Q1	148,282	$909,000	+$37,679	$7,000		$6.1	20
2016 Q4	139,267	$850,000	-$374,754		$0	$6.05	23
2016 Q3	181,737	$1,320,000	-$246,428	$0	$534,000	$7.26	21
2016 Q2	220,940	$1,841,000	+$300,003	$98,000	$918,000	$8.34	23
2016 Q1	201,186	$1,318,000	-$124,121	$135,000	$264,000	$6.65	24
2015 Q4	210,282	$1,781,840	+$388,209	$153,000	$349,000	$8.55	23
2015 Q3	156,424	$854,000	-$1,037,671	$0	$130,000	$5.47	18
2015 Q2	334,950	$1,904,000	-$1,476,942	$111,000	$385,000	$5.68	13
2015 Q1	543,520	$3,371,822	-$1,225,552	$88,000	$0	$6.37	14
2014 Q4	824,403	$3,758,000	-$864,806	$70,000	$50,000	$4.56	19
2014 Q3	1,375,959	$11,127,000	-$423,614	$223,000	$0	$8.07	18
2014 Q2	1,426,930	$13,726,430	+$928,265	$505,000	$127,000	$9.62	22
2014 Q1	1,311,737	$15,304,000	+$5,082,819		$1,000	$11.78	21